Ali J. Satvat
CIK: 0001621788
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 22, 2026BBIO
BridgeBio Pharma, Inc.
Award(A)Direct4K shares- - Jun 5, 2026CHRS
Coherus Oncology, Inc.
Award(A)Direct30K shares- - Jun 20, 2025BBIO
BridgeBio Pharma, Inc.
Award(A)Direct6.6K shares- - Jun 12, 2025CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
112K shares- - Dec 30, 2024BBIO
BridgeBio Pharma, Inc.
Exercise(M)Direct39.9K shares at avg. $16.68$665K - Dec 30, 2024BBIO
BridgeBio Pharma, Inc.
Exercise(M)Direct79.7K shares at avg. $10.99$876K - Dec 30, 2024BBIO
BridgeBio Pharma, Inc.
Exercise(M)Direct39.9K shares at avg. $26.21$1.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 22, 2026 |  BBIO BridgeBio Pharma, Inc. | Award(A) | 3,990 | - | $0 | Direct |
| Jun 5, 2026 |  CHRS Coherus Oncology, Inc. | Award(A) | 30,000 | - | $0 | Direct |
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | Award(A) | 6,589 | - | - | Direct |
| Jun 12, 2025 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 112,000 | - | - | Direct |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | Exercise(M) | 39,851 | $16.68 | $664,715 | Direct |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | Exercise(M) | 79,702 | $10.99 | $875,925 | Direct |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | Exercise(M) | 39,851 | $26.21 | $1,044,495 | Direct |
1-7 of 7 transactions
About Satvat Ali J.
Satvat Ali J. (SEC CIK 0001621788) files insider reports with the SEC as Director of BridgeBio Pharma, Inc. (BBIO) and Director of Coherus Oncology, Inc. (CHRS).
Signal8 holds 5 ownership filings by Satvat Ali J., all Form 4s, filed between Dec 31, 2024 and Jun 24, 2026. Those filings report 7 transactions, from Dec 30, 2024 to Jun 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Satvat Ali J.'s filings is in REDWOOD CITY, CA.
Recent filings by Satvat Ali J.
- Jun 22, 2026: Grant or award of BBIO shares (Form 4, code A).
- Jun 5, 2026: Grant or award of CHRS shares (Form 4, code A).
- Jun 20, 2025: Grant or award of BBIO shares (Form 4, code A).
- Jun 12, 2025: Grant or award of CHRS derivative securities (Form 4, code A).
- Dec 30, 2024: Option exercises of BBIO shares (3 lines, Form 4, code M).
Other insiders filing for BridgeBio Pharma, Inc. (BBIO)
- Kumar Neil, Chief Executive Officer
- Trimarchi Thomas, President and CFO
- Apuli Maricel, Chief Accounting Officer
- Ellis Andrea, Director
- Cook Jennifer E., Director
- Valantine Hannah, Director